"Fact is that Her-Vaxx works better than anticipated, ---...

"Fact is that Her-Vaxx works better than anticipated, --- confirmed several times by IMU / LC

therefore an inadequate deal was rejected" ---- To satisfy HC guidelines, I have to stick with " Hearsay ".

To support the second part, look back at the decisions the board made --- Her-Vaxx combo trials.
Additionally the Team Wiedermann has continued to develop more B-cell vaccines - unlikely it could have happened if IMU / Wiedermann had surrendered the IP.

Whatever decisions the board is making, we have to trust them. They are the experts, we aren't.

Regarding whether the big guys know about IMU or not - LC has stated "YES: a few times. Prof Wiedermann has good relationships with Pfizer Germany and the Covid vaccine developer due to the European Covid response. Maybe something could come from that corner due to EU-India health development programs. There are many articles available, here is one from this month:

https://www.europarl.europa.eu/RegData/etudes/ATAG/2023/747918/EPRS_ATA(2023)747918_EN.pdf

EU-India: cooperation on health - European Parliament

In line with the EU-India Strategic Partnership of 2004 and the EU approach to global health, the EU and India have long-standing cooperation on health.

People see only the sp, there is so much more to IMU, most got no idea what's to come. Many just focus on the USA / AUS due to the trial locations. But check IMU anns regarding the Her-Vaxx patents. That's been done for good reasons.

Be patient!!!!!!!!!!!!!, trust the board. Don't listen to "HC-Experts". And don't get scared by the low sp - take advantage of it if your funds allow it.

GLTA